GILD
NASDAQ
US
Gilead Sciences, Inc. - Common Stock
$139.71
▼ $-0.59
(-0.42%)
Vol 4.9M
12
Quality Score
ok
Deep Check
1/5
fail
Rev ✗
NI ✓
>IPO ✗
Mkt Cap
$152.3B
P/E
18.8
ROE
40.7%
Margin
27.9%
D/E
126.80
Beta
0.37
Div Yield
2.57%
52W
$89–$129
Wall Street Consensus
39 analysts · Apr 202611
Strong Buy
20
Buy
8
Hold
0
Sell
0
Strong Sell
79.5%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $1.85 | $1.86 | +$0.01 |
| Sep 2025 | $2.17 | $2.47 | +$0.30 |
| Jun 2025 | $2.00 | $2.01 | +$0.01 |
| Mar 2025 | $1.82 | $1.81 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $7.6B | $6.7B | $7.1B | $7.8B | $7.9B |
| Net Income | — | $1.8B | $1.3B | $2.0B | $3.1B | $2.2B |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 32.9% | 33.0% | 33.0% | 40.7% | 40.7% | 40.7% |
| P/E (TTM) | 21.85 | 23.57 | 22.21 | 18.33 | 19.03 | 18.78 |
| Net Margin | 27.7% | 21.9% | 21.9% | 27.9% | 27.9% | 27.9% |
| Gross Margin | 78.8% | 78.5% | 78.5% | 78.7% | 78.7% | 78.7% |
| D/E Ratio | 126.80 | 126.80 | 126.80 | 126.80 | 126.80 | 126.80 |
| Current Ratio | 1.32 | 1.32 | 1.32 | 1.53 | 1.53 | 1.53 |
Key Ratios
ROA (TTM)
14.1%
P/S (TTM)
5.24
P/B
6.0
EPS (TTM)
$6.43
CF/Share
$6.68
Rev Growth 3Y
+1.7%
52W High
$128.70
52W Low
$88.57
$88.57
52-Week Range
$128.70
Financial Health
Free Cash Flow
$3.1B
Net Debt
$17.4B
Cash
$7.6B
Total Debt
$24.9B
As of Dec 31, 2025
How does GILD compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GILD valuation vs Biotechnology peers
P/E ratio
18.8
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
5.2
▼
59%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
6.0
▲
142%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
2.6%
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GILD profitability vs Biotechnology peers
ROE
40.7%
▲
161%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
27.9%
▲
110%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
78.7%
▲
0%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
14.1%
▲
130%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
GILD financial health vs Biotechnology peers
D/E ratio
126.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.5
▼
66%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
61%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
GILD fundamentals radar
GILD
Peer median
Industry
GILD profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GILD vs peers: key metrics
Latest AI Opinion
Grok
BUY
Price action shows a clear pullback from the February 2026 peak of around $155 to the recent low of $136.44 last week, with the current price at $136.52 providing a solid entry point near support for a potential bounce in …
Mar 24, 2026Dividends
$3.19
/ year
Mar 13, 2026
$0.8200
Dec 15, 2025
$0.7900
Sep 15, 2025
$0.7900
Jun 13, 2025
$0.7900
Mar 14, 2025
$0.7900
Dec 13, 2024
$0.7700
Sep 13, 2024
$0.7700
Jun 14, 2024
$0.7700
Latest News
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
Yahoo Finance · Apr 04
Gilead Sciences To Acquire Ouro Medicines
Nasdaq · Mar 24
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
Yahoo Finance · Mar 18
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades
Yahoo Finance · Mar 17